New Anticoagulant Therapies: A Market Briefing

    Published: October 1, 2004 | Price: $895.00 – $1,790.00

    There is a pressing need for new anticoagulant therapeutics in human medicine. To meet this need, developers are reformulating traditional cornerstone therapeutics such as heparin and looking to new classes such as DTIs to prevent stroke and myocardial infarction and treat deep vein thrombosis and a host of other emerging indications. This briefing analyzes the potential world medical markets for new anticoagulant therapies. Revenue projections through 2010 are made for four geographic regions and for two potentially blockbuster products. This...
    U.S. Market for Over-the-Counter Gastrointestinal Products, 2nd Edition, The

    Published: August 1, 2004 | Price: $1,995.00 – $5,990.00

    The market for OTC Gastrointestinal products has gone through several significant changes in the past 5 years, most of which have to do with the Rx-to-OTC switches of two types of gastroesophageal reflux disease (GERD) drugs: H2 receptor antagonists and proton pump inhibitors (PPIs). This report on the U.S. market for OTC GI products presents a description of upper gastrointestinal conditions and diseases, the OTC treatments available, and clinical and business trends affecting the market, consumer behavior and attitudes, and...
    Ambulatory Infusion Pumps in Pain Management: A Market Briefing

    Published: August 1, 2004 | Price: $895.00 – $1,790.00

    After years of neglect, concerns over pain, how it is assessed and managed on a patient-by-patient basis have captured the attention of health care professionals and the public. There are a variety of issues that have acted to draw this attention, including the high prevalence of pain, continuing evidence that pain is undertreated and a growing awareness of the negative consequences of poor pain management. Infusion pumps were first introduced in the 1960s. These devices ushered in a whole new...
    Pharmaceutical Outsourcing Opportunities Post Launch: Contract Manufacturing, and Sales and Marketing

    Published: July 1, 2004 | Price: $3,500.00 – $7,000.00

    After decades of sustained growth and profitability, the pharmaceutical industry has been positioned as one of the few recession proof industries based on its performance through multiple economical cycles. In recent years, there have been visible strains in the pharmaceutical business. With a downturn in fortunes, many pharmaceutical companies are searching for business solutions to streamline operations and cut costs as they strive to continue generating above-average shareholder returns. Outsourcing has become an integral, ongoing element of pharmaceutical companies’ business...
    Market for Generic Biologics: Issues, Trends, and Market Potential, The

    Published: June 1, 2004 | Price: $1,500.00 – $3,000.00

    Biologics, or biopharmaceuticals, are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, biogenerics are not generic biologics, because there can technically be no generic form of biologics. That is, the complex process of creating biologics, means that traditional definitions of bioequivalence used in the generic drug industry do not (or may not)...
    Early Stage Drug Discovery 2004: Combi-chem & High Throughput Screening Revisited

    Published: June 1, 2004 | Price: $2,995.00 – $5,990.00

    Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to creep in: HTS and UHTS have not lived up to their hype. R&D productivity is not improving, in fact it may be declining. In the...
    Medicare Reform and the Pharmaceutical Industry: Implications of the Medicare Prescription Drug Improvement and Modernization Act of 2003

    Published: March 1, 2004 | Price: $795.00 – $1,590.00

    The hard-fought battle over Medicare's prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all the facts. This market briefing from Kalorama describes and assesses the provisions of the "Medicare Prescription Drug, Improvement and Modernization Act of 2003" and predicts...
    Growth Factor Inhibitors: Markets and Opportunities for a Growing Pipeline

    Published: March 1, 2004 | Price: $3,500.00 – $7,000.00

    Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or blocks the ability of cells to divide and multiply. Blood and tissue growth factors have become exciting targets for compounds intended to inhibit or slow the mechanisms involved in their function or growth. This report highlights the research into, and the current and potential key world markets for, products that...
    Cardiovascular Disease: The 45 Market in the United States for Drugs and Medical Devices

    Published: March 1, 2004 | Price: $2,995.00 – $5,990.00

    Cardiovascular disease includes chronic conditions such as hypertension, congestive heart failure and atherosclerosis, as well as such acute conditions as myocardial infarction and cardiac arrest. While cardiovascular disease may be diagnosed at any age, it is most prevalent in later years, particularly among sedentary individuals who are also overweight or obese. With the aging of the "Baby Boom" generation, a generation that has defined the term "couch potato" and has grown up on and maintained a diet of fast-food, the...
    U.S. Market for OTC Diet Aids, The

    Published: February 1, 2004 | Price: $3,000.00 – $6,000.00

    Diet Aids are among the most rapidly growing categories of over-the-counter (OTC) products. Between 1998 and 2003, growth was driven by two main factors: changes in laws and lawsuits relating to the industry, and changes in consumer attitudes toward weight loss. Because both of these factors are subject to rapid and unpredictable shifts, the diet aids category remains a highly volatile market. The consumer attitude towards OTC diet aids has shown extreme changes during the last couple of years. While...
    Worldwide Market for Prescription Dermatological Drugs – 4th Edition, The

    Published: February 1, 2004 | Price: $3,500.00 – $7,000.00

    This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fourth time Kalorama Information has comprehensively studied the dermatology markets. For this latest edition, Kalorama completely re-evaluated the market from the ground up, and in addition to the usual primary interviewing of industry participants, clinicians, and regulators, we also conducted scores of interviews with users of...
    Emerging Cancer Vaccine Market, The

    Published: February 1, 2004 | Price: $3,500.00 – $7,000.00

    Immunologic approaches to cancer therapy are not only increasing in reputation and number, but the market for these products is increasingly becoming a reality. Vaccines are in the forefront of this approach to cancer, and the handful of cancer vaccine products currently on the market for bladder, colon, and skin cancer are soon to be joined by many more with indications for more wide-spread forms, including lung, breast, ovarian, prostate, leukemia, and others. This new study from Kalorama discusses the...
    Outsourcing in Drug Development – The Contract Research Market from Preclinical to Phase III

    Published: January 1, 2004 | Price: $3,500.00 – $7,000.00

    The cost of drug development has soared during the past ten years compelling pharmaceutical and biotechnology companies to look for new, smarter ways of conducting clinical research. Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. This industry has evolved from providing limited clinical trial services...
    Type II Diabetes: The 45 Market in the United States for Drugs and Diagnostics

    Published: January 1, 2004 | Price: $2,995.00 – $5,990.00

    Type II diabetes is a metabolic disease the increases in incidence and prevalence with age. Type II diabetes (also known as "adult onset diabetes" and "non-insulin dependent diabetes") is a disease of glucose metabolism in which the individual becomes resistant to the glucose produced by the pancreas. As a result, glucose is not properly metabolized and serum glucose levels are increased, resulting in numerous complications vascular, renal, neurological and ophthalmological complications as the patient ages. This volume of the Markets...
    Drug Delivery Technology and Applications: A summary of Kalorama’s market research, 2001-2003

    Published: November 7, 2003 | Price: $746.00 – $1,492.00

    Over the past three years, Kalorama Information's analysts have studied drug delivery markets from several angles. In 2001 and 2002, we published a 5-volume series on drug delivery technology, each volume devoted to a route of administration: Volume I: Oral Drug Delivery Volume II: Injectable and Implantable Drug Delivery Volume III: Pulmonary Drug Delivery Volume IV: Transdermal and Transmucousal Drug Delivery Volume V: Advanced Drug Delivery This series segmented the market by technology and included an innovative analysis that estimated...